Influence of *IL-1R2* polymorphisms on endometrial cancer susceptibility in the Chinese Han population

Jiamin Wu¹* | Wenjie Zhang²* | Junhong Cai³ | Sizhe Huang⁴ | Fanglin Niu¹ | Ying Zhang³ | Shan Bao⁴ | Tianbo Jin¹,⁵

¹Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Northwest University, Xi’an, Shaanxi, China
²Department of Women’s Health Care, Northwest Women and Children Hospital, Xi’an, Shaanxi, China
³Key Laboratory of Cell and Molecular Genetic Translational Medicine in Hainan Province, Hainan General Hospital, Haikou, Hainan, China
⁴Department of Gynaecology and Obstetrics, Hainan General Hospital, Haikou, Hainan, China
⁵Key Laboratory for Basic Life Science Research of Tibet Autonomous Region, School of Medicine, Xizang Minzu University, Xianyang, Shaanxi, China

**Abstract**

**Background:** Recently, many studies have identified that genetic factor plays a crucial role in endometrial cancer development. The purpose of this study is to investigate the influence of single nucleotide polymorphisms (SNPs) of *IL-1R2* on endometrial cancer susceptibility.

**Methods:** We performed a case-control study that included 293 patients with endometrial cancer and 579 healthy controls. Six SNPs in the *IL-1R2* gene were genotyped using the Agena MassARRAY platform. Genetic models and haplotype analyses were used to assess the association between SNPs and endometrial cancer risk by computing odds ratios (ORs) and 95% confidence intervals (CIs).

**Results:** Overall analysis results found that two SNPs (rs4851527 and rs3218896) and haplotypes TGTC and TACT were significantly associated with endometrial cancer risk. Stratified analysis by age showed that rs2072472 was associated with endometrial cancer risk in age >54 subgroup.

**Conclusions:** These findings suggested that *IL-1R2* polymorphisms may contribute to the development of endometrial cancer. Further studies are required to confirm the results.

**Keywords**
endometrial cancer, *IL-1R2*, polymorphisms, susceptibility
1 | INTRODUCTION

Endometrial cancer is the most common type of gynecological malignancy worldwide and has a large geographic variation in incidence and mortality rates (Bray et al., 2018). In China, there has been a significant increase in the number of women diagnosed with endometrial cancer (Chen et al., 2016). Although early menarche, unopposed estrogen, endometriosis, late menopause, obesity, diabetes, hypertension, and nulliparity are well-known risk factors for the development of endometrial cancer (Amant et al., 2005), only a part of individuals exposed to these risk factors develop endometrial cancer during their lifetime, suggesting that genetic factors play a crucial role in endometrial cancer development. The single nucleotide polymorphism (SNP) is the most common form of human genetic variations. It has been reported that polymorphisms of interleukin genes are significantly associated with gynecologic cancers risk (Koensgen et al., 2015; Yu et al., 2015; Zhou et al., 2018). Recently, genome-wide association studies have identified many risk loci in the candidate endometrial cancer susceptibility genes, such as *HNF1B* (Painter et al., 2015), *LOC643623*, *AKT1*, and *KLF5* (Burki, 2016; Cheng et al., 2016). However, the mechanism of endometrial cancer is still unclear.

The association between inflammation and cancer has been recognized for some years and recently become the focus of tumor studies (Grivennikov, Greten, & Karin, 2010). It has also indicated the proinflammatory milieu can directly increase estrogen production, which may facilitate carcinogenesis by disrupting the estrogen-progesterone balance (Modugno, Ness, Chen, & Weiss, 2005). A growing number of studies reported that SNPs locus in interleukin (IL) genes, such as *IL-32* (Yu et al., 2015), *IL-6* (Wang, Zhang, Zheng, Liu, & Li, 2016), and *IL1A* (Yu et al., 2016), are associated with the risk endometrial cancer. Interleukin 1 receptor type 2 (IL-1R2) is located on the long arm of human chromosome 2 at band 2q12, belongs to the interleukin 1 receptor family (Boraschi & Tagliabue, 2013). *IL-1R2* serves as a negative regulator of IL-1 signaling by competing with *IL-1R1* for IL-1 and by complexing with IL-1 receptor accessory protein (IL-1RAP) once it binds IL-1, thereby sequestering both the ligand and the accessory protein required for signal transduction (Lang et al., 1998). *IL-1R2* is an important mediator involved in many cytokine induced immune and inflammatory responses (Peters, Joesting, & Freund, 2013).

Association studies between *IL-1R2* gene polymorphisms and diseases have been carried out recently (Ren, Dong, Huyan, Jin, & Chen, 2018; Xia et al., 2015; Xie et al., 2017). However, the influence of *IL-1R2* polymorphisms on endometrial cancer susceptibility in the Chinese Han population has not been reported yet. Given the role of *IL-1R2* in immune regulation and inflammatory response, we hypothesized that common genetic polymorphisms in the *IL-1R2* gene may also influence the risk of endometrial cancer. To investigate this hypothesis, we recruited 293 patients with endometrial cancer and 579 healthy controls to investigate the association between polymorphisms in the *IL-1R2* gene and endometrial cancer risk in the Chinese Han women population.

2 | MATERIALS AND METHODS

2.1 | Study participants

In this case-control study, a total of 293 female patients with new diagnosis of endometrial cancer were recruited from the Hainan General Hospital and the Northwest Women and Children Hospital. All cases were confirmed histologically to have endometrial cancer. The patients were recruited without restrictions of age, sex, or disease stage. The controls were 579 females randomly selected from a pool of healthy volunteers who visited the general health check-up center at the same hospitals during the same period. The mean age of the participants was 48.06 years in the control group and 59.31 years in the case group, respectively. Women who have a history of any cancer or hysterectomy were excluded in the study. The case and control subjects were Chinese Han population.

This study was performed in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of the Hainan General Hospital and the Northwest Women and Children Hospital. All of the participants voluntarily agreed to participate in this study and all provided written informed consent.

2.2 | Genotyping

We collected 5ml peripheral blood samples from each subject using venipuncture into ethylene diamine tetraacetic acid (EDTA)-coated blood vacutainer collection tubes and then stored at −80°C for further use. We used the GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag. Co. Ltd., Xi’an, China) to extract genomic DNA from blood samples following the manufacturer’s instructions. We assessed the purity and concentration of the extracted DNA using a spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA) by absorbance measurements at 260 and 280 nm.

Six SNPs (rs11674595, rs4851527, rs719250, rs3218896, rs3218977, and rs2072472) in *IL-1R2* with minor allele frequency (MAF) greater than 0.05 in the global population from the HapMap database and previously reported were adopted for analysis. We used the Agena Bioscience Assay Design Suite V2.0 software (https://agenacx.com/online-tools/) to design the primers of PCR amplification and extension of the six selected SNPs. These SNPs in *IL-1R2* were genotyped in the case and control groups using the Agena MassARRAY.
platform with iPLEX gold chemistry (Agena Bioscience, San Diego, CA) according to the manufacturer’s instructions. We used the Agena Bioscience TYPER software (version 4.0) to manage and analyze data.

2.3 | Statistical analysis

The Hardy–Weinberg equilibrium (HWE) was performed for each polymorphism among controls using the PLINK software (version 1.07) (Purcell et al., 2007). We compared the distributions of SNPs allele and genotype frequencies between cases and controls using \( \chi^2 \) test. The association analyses were conducted using logistic regression analysis under codominant, dominant, recessive, and additive genetic models with adjustment for age. Pair-wise linkage disequilibrium (LD) between the five SNPs was assessed using the Haploview software (version 4.2) (Barrett, Fry, Maller, & Daly, 2005). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the potential association between SNPs and endometrial cancer risk (Lin et al., 2017; Tian et al., 2018). Odds ratio less than 0.05 was considered statistically significant. All statistical tests were two-sided. The statistical analyses were performed using the Statistical Package of the Social Sciences (SPSS) software version 20.0 (SPSS Inc., Chicago, IL).

3 | RESULTS

The distributions of the genotype frequency of the six SNPs among the healthy controls were found to be in accordance with the HWE \( (p > 0.05) \). We used Pearson \( \chi^2 \) test to compare the distributions of the allele frequency of the SNPs in \( IL-1R2 \) between the case group and the control group (Table 1). However, the allele frequency of all the six SNPs in case group did not differ significantly compared to that in the control group \( (p > 0.05) \). There was no statistically significant association between the \( IL-1R2 \) polymorphisms and endometrial cancer risk in the Chinese Han population.

Next, we further evaluated the association between the \( IL-1R2 \) polymorphisms and endometrial cancer risk under the genetic models (codominant, dominant, recessive, and additive) by logistic regression analysis adjusting for age (Table 2). Compared with the GG wild-type homozygous genotype, the AG genotype of rs4851527 was associated with a decreased risk of endometrial cancer \( (OR = 0.71, 95\% CI: 0.52–0.96, p = 0.028) \). When the wild-type homozygous genotype GG was used as a reference, the variant homozygote AA and heterozygote AG genotypes were also found to be associated with a reduced risk of endometrial cancer in the dominant model \( (OR = 0.71, 95\% CI: 0.53–0.96, p = 0.024) \). Similar association was found between rs4851527 and the risk of endometrial cancer in the additive model \( (OR = 0.79, 95\% CI: 0.63–1.00, p = 0.047) \).

Additionally, we observed a statistically significant association between the rs3218896 polymorphism and endometrial cancer risk. The relative OR of 1.41 (95% CI: 1.00–1.97) showed that the variant heterozygote CT was correlated with a higher risk of developing endometrial carcinoma comparing with the wild-type homozygous genotype TT. A statistically significant interaction was observed between the variant homozygote CC and heterozygote CT genotypes of rs3218896 for an increased risk of endometrial cancer in the dominant model \( (OR = 1.41, 95\% CI: 1.02–1.96, p = 0.037) \). We also found that the SNP rs3218896 was significantly associated with an increased risk of endometrial cancer in the additive model \( (OR = 1.34, 95\% CI: 1.01–1.79, p = 0.043) \). However, no associations between the four \( IL-1R2 \) polymorphisms (rs11674595, rs719250, rs3218977, and rs2072472) and endometrial cancer risk were observed in the different genetic models.

The results of pair-wise LD analysis with these six SNPs are shown in Figure 1. We observed two small haplotype blocks;
TABLE 2  Genetic model analyses of the association between *IL-1R2* polymorphisms and endometrial cancer risk

| SNP-ID    | Model  | Genotype | Case  | Control | Without adjust OR (95% CI) | p     | Adjust OR (95% CI) | p     |
|-----------|--------|----------|-------|---------|----------------------------|-------|-------------------|-------|
| rs11674595 | Codominant | TT       | 182   | 350     | 1.00                        | 1.00  | 1.00              | 1.00  |
|           |        | CT       | 89    | 196     | 0.87 (0.64–1.19)             | 0.388 | 0.90 (0.65–1.24)  | 0.515 |
|           |        | CC       | 20    | 30      | 1.28 (0.71–2.32)             | 0.412 | 1.21 (0.65–2.25)  | 0.548 |
|           | Dominant | TT       | 182   | 350     | 1.00                        | 1.00  |                   |       |
|           |        | CC + CT  | 109   | 226     | 0.93 (0.69–1.24)             | 0.612 | 0.94 (0.70–1.27)  | 0.699 |
|           | Recessive | TT + CT  | 271   | 546     | 1.00                        | 1.00  |                   |       |
|           |        | CC       | 20    | 30      | 1.34 (0.75–2.41)             | 0.322 | 1.25 (0.68–2.31)  | 0.468 |
|           | Additive | –        | –     | –       | 1.00 (0.79–1.26)             | 0.979 | 1.00 (0.78–1.27)  | 0.977 |
| rs4851527  | Codominant | GG       | 163   | 272     | 1.00                        | 1.00  |                   |       |
|           |        | AG       | 105   | 258     | 0.68 (0.50–0.92)             | 0.011 | 0.71 (0.52–0.96)  | 0.028 |
|           |        | AA       | 25    | 49      | 0.85 (0.51–1.43)             | 0.544 | 0.74 (0.43–1.28)  | 0.280 |
|           | Dominant | GG       | 163   | 272     | 1.00                        | 1.00  |                   |       |
|           |        | AA + AG  | 130   | 307     | 0.71 (0.53–0.94)             | 0.016 | 0.71 (0.53–0.96)  | 0.024 |
|           | Recessive | GG + AG  | 268   | 530     | 1.00                        | 1.00  |                   |       |
|           |        | AA       | 25    | 49      | 1.01 (0.61–1.67)             | 0.972 | 0.86 (0.51–1.46)  | 0.580 |
|           | Additive | –        | –     | –       | 0.81 (0.65–1.01)             | 0.063 | 0.79 (0.63–1.00)  | 0.047 |
| rs719250   | Codominant | GG       | 137   | 289     | 1.00                        | 1.00  |                   |       |
|           |        | AG       | 125   | 231     | 1.14 (0.85–1.54)             | 0.384 | 1.25 (0.92–1.71)  | 0.152 |
|           |        | AA       | 31    | 59      | 1.11 (0.69–1.79)             | 0.674 | 1.20 (0.73–1.97)  | 0.470 |
|           | Dominant | GG       | 137   | 289     | 1.00                        | 1.00  |                   |       |
|           |        | AA + AG  | 156   | 290     | 1.14 (0.86–1.50)             | 0.379 | 1.24 (0.93–1.67)  | 0.145 |
|           | Recessive | GG + AG  | 262   | 520     | 1.00                        | 1.00  |                   |       |
|           |        | AA       | 31    | 59      | 1.04 (0.66–1.65)             | 0.858 | 1.08 (0.67–1.74)  | 0.745 |
|           | Additive | –        | –     | –       | 1.08 (0.88–1.34)             | 0.458 | 1.15 (0.92–1.43)  | 0.215 |
| rs3218896  | Codominant | TT       | 203   | 433     | 1.00                        | 1.00  |                   |       |
|           |        | CT       | 81    | 133     | 1.30 (0.94–1.79)             | 0.112 | 1.41 (1.00–1.97)  | 0.048 |
|           |        | CC       | 8     | 12      | 1.42 (0.57–3.53)             | 0.448 | 1.50 (0.58–3.85)  | 0.401 |
|           | Dominant | TT       | 203   | 433     | 1.00                        | 1.00  |                   |       |
|           |        | CC + CT  | 89    | 145     | 1.31 (0.96–1.79)             | 0.091 | 1.41 (1.02–1.96)  | 0.037 |
|           | Recessive | TT + CT  | 284   | 566     | 1.00                        | 1.00  |                   |       |
|           |        | CC       | 8     | 12      | 1.33 (0.54–3.29)             | 0.539 | 1.37 (0.54–3.51)  | 0.509 |
|           | Additive | –        | –     | –       | 1.26 (0.96–1.66)             | 0.094 | 1.34 (1.01–1.79)  | 0.043 |

(Continues)
| SNP-ID | Model   | Genotype | Case | Control | Without adjust OR (95% CI) | p       | Adjust OR (95% CI) | p       |
|--------|---------|----------|------|---------|----------------------------|---------|-------------------|---------|
| rs3218977 | Codominant | GG       | 163  | 341     | 1.00                        | 1.00    | 1.00              | 1.00    |
|         |         | AG       | 111  | 216     | 1.08 (0.80–1.44)            | 0.631   | 1.05 (0.77–1.43)  | 0.747   |
|         |         | AA       | 17   | 22      | 1.62 (0.84–3.13)           | 0.154   | 1.28 (0.65–2.54)  | 0.475   |
|         | Dominant | GG       | 163  | 341     | 1.00                        |         | 1.00              |         |
|         |         | AA + AG  | 128  | 238     | 1.13 (0.85–1.50)           | 0.417   | 1.08 (0.80–1.44)  | 0.628   |
|         | Recessive| GG + AG  | 274  | 557     | 1.00                        |         | 1.00              |         |
|         |         | AA       | 17   | 22      | 1.57 (0.82–3.01)           | 0.173   | 1.26 (0.64–2.46)  | 0.505   |
|         | Additive | –        | –    | –       | 1.16 (0.91–1.47)           | 0.239   | 1.09 (0.85–1.39)  | 0.515   |
| rs2072472 | Codominant | TT       | 174  | 360     | 1.00                        | 1.00    |                   |         |
|         |         | CT       | 96   | 188     | 1.06 (0.78–1.43)           | 0.724   | 1.09 (0.80–1.50)  | 0.586   |
|         |         | CC       | 22   | 31      | 1.47 (0.83–2.61)           | 0.191   | 1.44 (0.79–2.64)  | 0.232   |
|         | Dominant | TT       | 174  | 360     | 1.00                        |         | 1.00              |         |
|         |         | CC + CT  | 118  | 219     | 1.12 (0.84–1.49)           | 0.459   | 1.14 (0.85–1.54)  | 0.382   |
|         | Recessive| TT + CT  | 270  | 548     | 1.00                        |         | 1.00              |         |
|         |         | CC       | 22   | 31      | 1.44 (0.82–2.54)           | 0.206   | 1.40 (0.77–2.53)  | 0.265   |
|         | Additive | –        | –    | –       | 1.14 (0.90–1.43)           | 0.275   | 1.15 (0.91–1.46)  | 0.254   |

Note. 95% CI: 95% Confidence interval; OR: Odds ratio; SNP: Single nucleotide polymorphism.

Adjust OR and 95% CI were calculated using a conditional logistic regression adjusted with age. p < 0.05 was considered statistically significant.
first composed of rs11674595, rs4851527, rs719250, and rs3218896; second of rs3218977 and rs2072472. The distributions of the frequencies of the haplotypes TGTC and TACT were significantly different between endometrial cancer and control groups \((p = 0.031\) and \(p = 0.049\), respectively). Logistic regression analysis confirmed that the haplotypes TGTC \((OR = 0.73, 95\% CI: 0.54–0.97)\) and TACT \((OR = 0.79, 95\% CI: 0.63–1.00)\) were significantly associated with decreased endometrial cancer risk after adjusting for age (Table 3). Moreover, the haplotype AA was found to be significantly associated with a reduced risk of endometrial cancer before adjusting for age \((OR = 0.81, 95\% CI: 0.67–0.99, p = 0.044)\) (Table 3).

Given that age is a major endometrial cancer risk factor, we further evaluated the association between polymorphisms of \(IL-1R2\) and endometrial cancer risk by age stratified analysis (Table 4). The CC genotype of rs2072472 was found to be associated with an increased risk of endometrial cancer compared with the TT wild-type homozygous genotype in age >54 years old subgroup \((OR = 2.28, 95\% CI: 1.04–5.00, p = 0.040)\). When compared with the variant homozygote TT and heterozygote CT genotypes, the genotype CC was also found to be associated with an increased risk of endometrial cancer in the recessive model in the subgroup of age >54 years \((OR = 2.33, 95\% CI: 1.08–5.03, p = 0.032)\).

4 | DISCUSSION

In this study, we investigate the influence of \(IL-1R2\) polymorphisms on endometrial cancer susceptibility in the Chinese Han population. Overall analysis results found that rs4851527 was associated with a decreased risk of endometrial cancer; rs3218896 was significantly associated with an increased risk of endometrial cancer. Haplotype analysis confirmed that the haplotypes TGTC and TACT were significantly associated with decreased endometrial cancer risk. Moreover, stratification analysis showed that rs2072472 was associated with an increased risk of endometrial cancer in age >54 subgroup.

| SNP-ID | Haplotype | FA   | FU   | OR (95%CI) | \(p\)     | Adjust OR (95%CI) | Adjust \(p\) |
|--------|-----------|------|------|------------|----------|--------------------|-------------|
| rs11674595<rs4851527<rs719250<rs3218896 | TGTC     | 0.835| 0.866| 0.78 (0.59–1.03) | 0.080   | 0.73 (0.54–0.97)  | 0.031       |
| rs11674595<rs4851527<rs719250<rs3218896 | TGTT     | 0.848| 0.837| 1.09 (0.83–1.44) | 0.530   | 1.04 (0.78–1.38) | 0.778       |
| rs11674595<rs4851527<rs719250<rs3218896 | TACT     | 0.266| 0.309| 0.81 (0.65–1.01) | 0.063   | 0.79 (0.63–1.00) | 0.049       |
| rs11674595<rs4851527<rs719250<rs3218896 | CGCT     | 0.778| 0.781| 0.98 (0.78–1.24) | 0.879   | 0.98 (0.77–1.25) | 0.860       |
| rs11674595<rs4851527<rs719250<rs3218896 | TGCT     | 0.807| 0.829| 0.86 (0.66–1.12) | 0.257   | 0.93 (0.71–1.21) | 0.577       |
| rs3218977<rs2072472 | AG       | 0.759| 0.784| 0.87 (0.69–1.10) | 0.244   | 0.86 (0.68–1.10) | 0.227       |
| rs3218977<rs2072472 | GA       | 0.75 | 0.776| 0.86 (0.68–1.10) | 0.224   | 0.92 (0.71–1.17) | 0.487       |
| rs3218977<rs2072472 | AA       | 0.509| 0.56 | 0.81 (0.67–0.99) | 0.044   | 0.84 (0.68–1.04) | 0.105       |

Note. 95% CI: 95% Confidence interval; FA: Frequency in case; FU: Frequency in control; OR: Odds ratio. OR and 95% CI were calculated using a conditional logistic regression. \(p\) value < 0.05 indicates statistical significance.
IL-1R2 was first characterized by McMahon et al. in 1991 and natively found on neutrophils, B-cells, monocytes, and macrophages (McMahan et al., 1991). IL-1R2 serves as an endogenous inhibitor of IL-1 signaling by competing with IL-1R1 for IL-1, and by subsequently forming a complex with IL-1RAcP, thereby sequestering both the ligand and the accessory protein required for signal transduction (Schluter, Schelmbauer, Karram, & Mufazalov, 2018). Additionally, IL-1R2 exists in both a membrane bound and soluble form (sIL-1R2) that has biological properties similar to both a decoy receptor and a binding protein (Peters et al., 2013). Study found that IL-1R2 regulates the cell metabolism and the response of immune inflammation induced by many cytokines (Dinarello, 1994). These suggest that IL-1R2 is an important mediator involved in many cytokine induced immune and inflammatory responses. Inflammation aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and thus initiate and promote neoplastic transformation (Mantovani, Allavena, Sica, & Balkwill, 2008). It has reported that a proinflammatory milieu can also directly increase estrogen production, and then promotes the development of endometrial cancer (Modugno et al., 2005).

In this study, our results observed that rs4851527 and rs2072472 were associated with decreased risk of endometrial cancer, and rs3218896 was significantly associated with an increased risk of endometrial cancer. Previous study reported that the SNP rs4851527 was associated with an increased risk of IgA nephropathy in the over-dominant model (GA vs. GG-AA) (Xie et al., 2015). However, association studies indicated that rs4851527 was associated with decreased risk of tuberculosis (Ren et al., 2018) and ankylosing spondylitis (Xia et al., 2015). No significant association was found between rs4851527 and the risk of ankylosing spondylitis (Xia et al., 2015) and endometriosis (Chun et al., 2012). Previous study reported that rs3218977 was found to be associated with a 0.71-fold decrease risk of IgA nephropathy in the dominant model (GA-GG vs. AA) (Xie et al., 2017). A case-control association study found that the SNP rs3218977 was associated with an increased risk of aggressive periodontitis in the additive model in the Japanese (Kamei et al., 2014). However, rs3218977 was associated with an increased risk of tuberculosis in the dominant model (Ren et al., 2018). However, no significant association was also found between rs3218977 and risk of endometrial cancer in this study. These inconsistencies may be explained by the genetic polymorphism which may have different effects on diseases.

Some potential limitations of the present study should be considered when interpreting the results. First, our result is the first to find that the IL-1R2 polymorphisms were associated with the risk of endometrial cancer in the Chinese Han population. Therefore, additional studies are needed to confirm the association between IL-1R2 polymorphisms and endometrial cancer risk with large samples. Second, the potential risk factors such as early menarche, unopposed estrogen, late menopause, and obesity were not analyzed in this study due to the lack of relevant clinical data. More clinical and experimental data were needed to be collected to help us understand better the role of IL-1R2 polymorphisms in the development of endometrial cancer. Third, the biological functions of these SNPs were not analyzed. The expression level of the IL-1R2 gene should also be measured in future studies to assess the effects of polymorphisms on IL-1R2 gene.

### Table 4

| Model     | Genotype | Age ≤54 years old |          |          | Age >54 years old |          |          |
|-----------|----------|-------------------|----------|----------|-------------------|----------|----------|
|           |          | Case | Control | OR (95%CI) | p       | Case | Control | OR (95%CI) | p       |
| Codominant| TT       | 83   | 238     | 1.00      |          | 91   | 122     | 1.00      |          |
|           | CT       | 43   | 133     | 0.94 (0.61–1.46) | 0.785 | 53   | 55      | 1.30 (0.82–2.08) | 0.268 |
|           | CC       | 14   | 18      | 2.28 (1.04–5.00) | 0.040 | 8    | 13      | 0.77 (0.30–1.96) | 0.586 |
| Dominant  | TT       | 83   | 238     | 1.00      |          | 91   | 122     | 1.00      |          |
|           | CC + CT  | 57   | 151     | 1.10 (0.73–1.65) | 0.660 | 61   | 68      | 1.20 (0.77–1.86) | 0.422 |
| Recessive | TT + CT  | 126  | 371     | 1.00      |          | 144  | 177     | 1.00      |          |
|           | CC       | 14   | 18      | 2.33 (1.08–5.03) | 0.032 | 8    | 13      | 0.71 (0.28–1.77) | 0.458 |
| Additive  |          | –    | –       | 1.22 (0.88–1.69) | 0.225 | –    | –       | 1.06 (0.75–1.51) | 0.729 |

**Note.** 95% CI: 95% Confidence interval; OR: Odds ratio. 

*p < 0.05* was considered statistically significant.

5 | CONCLUSIONS

In conclusion, the present study results indicated that rs4851527, rs3218896, and rs2072472 in the IL-1R2 gene were associated with endometrial cancer susceptibility in the Chinese Han population.
population. These findings suggested that IL-1R2 polymorphisms may contribute to the development of endometrial cancer. However, further studies are required to confirm the results of the study with a large sample and investigate the detailed mechanisms of the variants that affect IL-1R2 gene function.

ACKNOWLEDGMENTS
This study was supported by the Opening Foundation of Key Laboratory of Resource Biology and Biotechnology in Western China (Northwest University), Ministry of Education (No. ZSK2017004).

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

ORCID
Shan Bao https://orcid.org/0000-0003-2139-0151

REFERENCES

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899. https://doi.org/10.1016/j.cell.2010.01.025

Kamei, H., Ishihara, Y., Fuma, D., Niwa, T., Kamiya, Y., Yokoi, T., … Kojima, T. (2014). Interleukin-1 receptor gene variants are associated with aggressive periodontitis in the Japanese. Archives of Oral Biology, 59(7), 756–763. https://doi.org/10.1016/j.archoralbio.2014.04.006

Koensgen, D., Bruennert, D., Ungureanu, S., Sofroni, D., Braicu, E. I., Schouli, J., … Mustea, A. (2015). Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine, 71(2), 334–338. https://doi.org/10.1016/j.cyto.2014.07.254

Lang, D., Knop, J., Wescie, H., Raffetseder, U., Kurrle, R., Boraschi, D., & Martin, M. U. (1998). The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: A novel mechanism of regulation of IL-1 responsiveness. Journal of Immunology, 161(12), 6871–6877.

Lin, S., Wang, M., Liu, X., Zhu, W., Guo, Y., Dai, Z., … Dai, Z. (2017). Association of genetic polymorphisms in MIF with breast cancer risk in Chinese women. Clinical and Experimental Medicine, 17(3), 395–401. https://doi.org/10.1007/s10238-016-0439-9

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444. https://doi.org/10.1038/nature07205

McManus, C. J., Slack, J. I., Mosley, B., Cosman, D., Lupton, S. D., Brunton, L. L., … Brannan, C. I. (1991). A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. The EMBO Journal, 10(10), 2821–2832. https://doi.org/10.1002/j.1460-2075.1991.tb07831.x

Modugno, F., Ness, R. B., Chen, C., & Weiss, N. S. (2005). Inflammation and endometrial cancer: A hypothesis. Cancer Epidemiology Biomarkers & Prevention, 14(12), 2840–2847. https://doi.org/10.1158/1055-9965.EPI-05-0493

Painter, J. N., O’Mara, T. A., Batra, J., Cheng, T., Lose, F. A., Dennis, J., … Spurdle, A. B. (2015). Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 24(5), 1478–1492. https://doi.org/10.1093/hmg/ddu552

Peters, V. A., Joesting, J. J., & Freund, G. G. (2013). IL-1 receptor 2 (IL-1R2) and its role in immune regulation. Brain, Behavior, and Immunology, 32, 1–8. https://doi.org/10.1016/j.bbi.2012.11.006

Porcelli, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., … Shar, P. C. (2007). PLINK: A tool set for whole-genome association and population-based linkage analyses. American Journal of Human Genetics, 81(3), 559–575. https://doi.org/10.1086/519795

Ren, G., Dong, Q., Huyan, B., Jin, P., & Chen, M. (2018). IL1R1 and IL1R2 polymorphisms were associated with tuberculosis risk: A pilot study. The Journal of Gene Medicine, 20, e3057. https://doi.org/10.1002/jgm.3057

Schloter, T., Schelmmbauer, C., Karram, K., & Mufazalav, I. A. (2018). Regulation of IL-1 signaling by the decoy receptor IL-1R2. Journal of Molecular Medicine, 96(10), 983–992. https://doi.org/10.1007/s00109-018-1684-z

Tian, T., Wang, M., Zheng, Y., Yang, T., Zhu, W., Li, H., & Zhou, L. (2018). Association of two FOXP3 polymorphisms with breast cancer susceptibility in Chinese Han women. Cancer Management and Research, 10, 867–872. https://doi.org/10.2147/CMAR.S158433

Wang, H. Y., Zhang, J. J., Zheng, X. Y., Liu, J. H., & Li, Y. W. (2016). Association between IL-6 Gene (-174 & -572 G/C)
Polymorphisms and Endometrial Adenocarcinoma Risk. Pathology Oncology Research, 22(4), 825–829. https://doi.org/10.1007/s12253-016-0073-6

Xia, Y. u., Liu, Y.-Q., Chen, K., Wang, L.-C., Ma, C.-Y., & Zhao, Y.-R. (2015). Association of IL-1R2 genetic polymorphisms with the susceptibility of ankylosing spondylitis in Northern Chinese Han population. Modern Rheumatology, 25(6), 908–912. https://doi.org/10.1007/s14397595.2015.1024302

Xie, M., Zhang, D., Zhang, Y., Yang, X., Su, Y., Wang, Y., … Su, H. (2017). Association of genetic polymorphisms in IL-1R1 and IL-1R2 genes with IgA nephropathy in the Han Chinese population. Oncotarget, 8(31), 50673–50679. https://doi.org/10.18632/oncotarget.16929

Yu, X., Zhou, B., Zhang, Z., Lan, Z., Chen, P., Duan, R., & Xi, M. (2016). Insertion/deletion polymorphism in IL1A 3’-UTR is associated with susceptibility to endometrial cancer in Chinese Han women. The Journal of Obstetrics and Gynaecology Research, 42(8), 983–989. https://doi.org/10.1111/jog.12989

Yu, X., Zhou, B., Zhang, Z., Gao, Q., Wang, Y., Song, Y., … Xi, M. (2015). Significant association between IL-32 gene polymorphisms and susceptibility to endometrial cancer in Chinese Han women.

Zhou, L., Zheng, Y. i., Tian, T., Liu, K., Wang, M., Lin, S., … Dai, Z. (2018). Associations of interleukin-6 gene polymorphisms with cancer risk: Evidence based on 49,408 cancer cases and 61,790 controls. Gene, 670, 136–147. https://doi.org/10.1016/j.gene.2018.05.104

Zuo, X., Li, M., Yang, Y. A., Liang, T., Yang, H., Zhao, X., & Yang, D. (2018). Interleukin gene polymorphisms in Chinese Han population with breast cancer, a case-control study. Oncotarget, 9(26), 17994–18001. https://doi.org/10.18632/oncotarget.23157

How to cite this article: Wu J, Zhang W, Cai J, et al. Influence of IL-1R2 polymorphisms on endometrial cancer susceptibility in the Chinese Han population. Mol Genet Genomic Med. 2019;7:e650. https://doi.org/10.1002/mgg3.650